Invega

Schizophrenia, Schizoaffective Disorder, Antidepressants + 3 more
Treatment
20 Active Studies for Invega

What is Invega

PaliperidoneThe Generic name of this drug
Treatment SummaryPaliperidone is a drug used to treat schizophrenia. It works by blocking signals from dopamine, serotonin, and other neurotransmitters in the brain. Paliperidone was approved by the FDA in 2006 and is available in tablet form or as an injection given once a month or every three months.
Invegais the brand name
image of different drug pills on a surface
Invega Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Invega
Paliperidone
2006
81

Effectiveness

How Invega Affects PatientsPaliperidone is an antipsychotic medication developed by Janssen Pharmaceutica. It is made from the same active ingredient as the older antipsychotic risperidone. How it works is still not clear, but it is thought to work in a similar way to risperidone.
How Invega works in the bodyPaliperidone is the active part of a drug used to treat schizophrenia. We don't know exactly how it works, but research suggests that it blocks the effects of dopamine and serotonin on the brain. Blocking these chemicals helps to reduce the symptoms of schizophrenia.

When to interrupt dosage

The proposed dosage of Invega is contingent upon the determined condition, like Therapeutic procedure, Schizophrenia and Mood stabilizing agents. The amount of dosage is subject to the technique of delivery listed in the table beneath.
Condition
Dosage
Administration
Schizophrenia
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Schizoaffective Disorder
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Mood stabilizing agents
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Antidepressants
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Therapeutic procedure
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Therapeutic procedure
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular

Warnings

There are 20 known major drug interactions with Invega.
Common Invega Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Paliperidone.
Acepromazine
Major
Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Alfuzosin
Major
Paliperidone may increase the hypotensive activities of Alfuzosin.
Amisulpride
Major
Paliperidone may increase the antipsychotic activities of Amisulpride.
Aripiprazole lauroxil
Major
Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.
Invega Toxicity & Overdose RiskOverdosing on this drug may lead to confusion, seizures, or spasms of the head and neck, which could increase the risk of inhaling vomit if emesis is induced.
image of a doctor in a lab doing drug, clinical research

Invega Novel Uses: Which Conditions Have a Clinical Trial Featuring Invega?

221 active clinical trials are currently in progress to evaluate the potential of Invega for Schizoaffective Disorder, Schizophrenia and Mood stabilizing agent therapy.
Condition
Clinical Trials
Trial Phases
Therapeutic procedure
0 Actively Recruiting
Schizophrenia
97 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2
Mood stabilizing agents
0 Actively Recruiting
Schizoaffective Disorder
43 Actively Recruiting
Phase 4, Phase 1, Phase 2, Not Applicable, Phase 3
Antidepressants
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting

Invega Reviews: What are patients saying about Invega?

5Patient Review
5/9/2019
Invega for Bipolar I Disorder with Most Recent Episode Mixed
Though it effectively treats mania, I hope to stop taking this medication soon because of the side effects that come with it.
5Patient Review
4/14/2020
Invega for Schizophrenia
This medication has been effective in keeping my voices at bay. I found coupons for it online that made it much more affordable.
5Patient Review
8/11/2022
Invega for Bipolar Disorder in Remission
I receive a monthly injection of Invega for bipolar disorder with psychosis, and it has been excellent for me! I can think more clearly and feel more positive about myself. As for the weight gain, I find myself hungry every couple hours, but I eat healthy and drink a lot of water. Great medication that has changed my life.
4Patient Review
8/7/2015
Invega for Schizophrenia
The weight gain is really the only downside to this medication; other than that, it's quite good.
4Patient Review
1/18/2022
Invega for Schizophrenia With Mood Changes
Invegga successfully cured my delusions and psychotic behavior. However, I have noted several side effects including lack of motivation, excessive sleeping, increased appetite, and weight gain. Additionally, I experience anxiety and dizziness frequently.
3.7Patient Review
4/20/2017
Invega for Bipolar Depression
Invega did a great job of stopping my delusional thoughts and psychosis. However, I gained 80 pounds in just six months from the shot. I know this for sure because I stopped taking the pill before and lost 40 pounds--so it's definitely the Invega that caused the weight gain. Hopefully I can try something else soon that will be more effective.
3Patient Review
3/25/2018
Invega for Bipolar Depression
I've been on this medication for a week now, and I'm not sure how much longer I'll continue taking it. I came off of Risperdal because I gained 40lbs in two months, and while Invaga 3mg hasn't caused me to gain as much weight, I am starting to feel suffocated when I sleep.
3Patient Review
9/23/2021
Invega for Schizophrenia
I would say that this drug is effective more often than not. It's helped me for seven years now.
2.3Patient Review
9/12/2016
Invega for Schizophrenia
I would not want this drug anywhere near me. I'm pretty sure it destroyed my ability to orgasm and caused severe anxiety with uncontrolled movements, etc. Only when I stopped taking the drug and it had a chance to exit my system did the anxiety subside! I feel like my brain has been re-wired, having zero interest in sex, or possibly even being able to reach climax impossible. Yes, it did help with hallucinations, but NOT WORTH IT IN MY BOOK!
1Patient Review
9/22/2022
Invega for Schizophrenia
My brother was given this shot and ended up in the ICU. He now has to learn how to walk again. This drug is incredibly dangerous and needs to be recalled immediately.
1Patient Review
1/27/2021
Invega for Schizophrenia
Invega is NOT effective, and made me feel incredibly lazy. I would advise against taking this drug, based on my experience.
1Patient Review
10/29/2019
Invega for Schizophrenia
Invega caused me to gain 65lbs, and I now have high cholesterol, extremely high triglycerides, high liver enzymes, high blood pressure, high Prolactin, and prediabetes. In 2 1/2 years I was never told about my blood work nor was I refered to my primary care physician until I was at "very high risk of a stroke or heart attack at any moment".
1Patient Review
5/30/2021
Invega for Bipolar Depression
I absolutely hated this drug. It made me feel terrible and I crashed my truck while on it. Northern Human Services in Conway, NH forced me to take it and I would strongly recommend against it.
1Patient Review
6/19/2022
Invega for Additional Medications to Treat Depression
This shot is the worst. It gave me depression and anxiety, and I exchanged one illness for another. I had voices before, but now I have full-blown depression and anxiety. I'm glad I'm getting off this medication because it is terrible.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about invega

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does INVEGA do to the brain?

"Invega is designed to correct the imbalance of certain neurotransmitters in the brain, specifically dopamine and serotonin. Its chemical structure is similar to Risperdal's, but it often produces fewer extrapyramidal side effects (tremor, stiffness, etc.)."

Answered by AI

How does INVEGA make you feel?

"Avoid becoming overheated or dehydrated in hot weather or during exercise.

If you are taking INVEGA®, you may feel dizzy, sleepy, or less alert. Be careful when driving or operating machinery until you know how this medicine will affect you. You may be more sensitive to heat while taking this medication. Avoid overheating or becoming dehydrated in hot weather or during exercise."

Answered by AI

What is the drug INVEGA used for?

"Paliperidone is a medication that works in the brain by restoring the balance of dopamine and serotonin. This improves thinking, mood, and behavior in people with schizophrenia and schizoaffective disorder."

Answered by AI

What does INVEGA do to a normal person?

"Invega is a medication that helps restore the balance of certain neurotransmitters in the brain. Invega specifically affects dopamine and serotonin. It is similar to Risperdal in how it works, but often has fewer side effects."

Answered by AI

What are the side effects of taking INVEGA?

"The following side effects may occur: drowsiness, dizziness, lightheadedness, drooling, stomach/abdominal pain, weight gain, or tiredness. If you experience any of these side effects, talk to your doctor. Dizziness and lightheadedness can make you more likely to fall. To avoid falling, get up slowly when you stand up from a sitting or lying position."

Answered by AI

Clinical Trials for Invega

Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of Mayo Clinic in Rochester, United States.

Weight Loss Medications for Obesity in Bipolar Disorder

18 - 65
All Sexes
Rochester, MN
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in patients with bipolar disorder ages 18-65. The main questions it aims to answer are: * Can the investigators compare the distribution of obesity characteristics (hungry brain, hungry gut, emotional hunger) between bipolar patients and non-bipolar participants (comparing from IRB #24-002375)? * Can the investigators evaluate the feasibility of anti-obesity medication (AOM) in patients with bipolar disorder? Participation will last for about 17-18 weeks and includes 7 in-person study visits, 4 phone call visits, and 12 virtual group therapy sessions. The first visit lasts about 2 hours and includes going over the informed consent form, a diagnostic interview to confirm diagnosis, gathering vital signs, mood questionnaires, an ECG, and urine drug and pregnancy tests (if applicable). The second visit lasts about 6-7 hours and involves multiple procedures and completing questionnaires to determine which study drug would allow participants to lose weight most effectively. At the third visit, participants will be assigned to take one of three FDA approved medications for weight loss: Semaglutide (Wegovy®), Naltrexone/Bupropion (Contrave®), or Phentermine/Topiramate (Qysmia®). It is possible that participants could be assigned to a group that receives no study medication. All participants will be enrolled in a 12-week virtual group therapy program targeted for weight loss. On this third visit the investigators will also gather vital signs, and participants will give a sample of blood. After the third visit, participants will come in for study visits every 4 weeks for 16 weeks (4 visits) to assess medication adherence, vitals, and answer questions about mood and eating (participants will also give a sample of blood at the 8-week and 16-week visits). Every two weeks in between in-person visits, the study team will call participants to assess medication adherence. Participants will be compensated for time spent in this study.
Phase 4
Waitlist Available
Mayo ClinicMark A Frye, M.D.
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric HospitalHeather Ward, MD
Have you considered Invega clinical trials? We made a collection of clinical trials featuring Invega, we think they might fit your search criteria.Go to Trials
Have you considered Invega clinical trials? We made a collection of clinical trials featuring Invega, we think they might fit your search criteria.Go to Trials
Image of Case Western Reserve University in Cleveland, United States.

Psychosocial Rehabilitation for Schizophrenia

18 - 50
All Sexes
Cleveland, OH
The purpose of this study is to understand how different types of community-based mental health care affect thinking abilities, daily functioning, and brain activity in adults with schizophrenia and related conditions. The investigators are especially interested in learning whether the Clubhouse Model-a structured, supportive community for individuals with mental illness-has unique benefits compared to standard outpatient mental health services. If participants decide to join, they will be asked to complete a total of six study visits with the research team over the course of your participation. Three of these study visits are at the beginning (baseline) and the remaining three are six months later. Two of the three visits will includes interviews, questionnaires, and thinking and memory tasks (cognitive testing) and one session will be an MRI brain scan, which is a safe and non-invasive imaging procedure. The total time required for each visit will be approximately 90 minutes to two hours. Participants may take breaks as needed.
Waitlist Available
Has No Placebo
Case Western Reserve UniversityJessica A Wojtalik, PhD
Have you considered Invega clinical trials? We made a collection of clinical trials featuring Invega, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security